This is a routine AGM circular with no trading catalyst. The addition of Dr. Steve Farr to the board adds rare-disease drug development expertise but is not a near-term stock mover. Monitor the company's clinical pipeline updates and future earnings filings for material developments.
Price Chart
Executive Summary
Bright Minds Biosciences filed its management information circular for the March 31, 2026 annual general meeting. The circular covers routine matters: election of six directors (including one new nominee, Dr. Steve Farr), reappointment of auditor De Visser Gray LLP, and advisory receipt of annual financial statements. No material financial data, earnings, or operational catalysts are disclosed — this is a standard proxy solicitation filing with no stock-moving content.
Key Facts
- AGM scheduled for March 31, 2026 at 10:00 a.m. PT in Vancouver, BC
- Shareholders to elect six directors: five incumbents plus new nominee Dr. Steve Farr (former Zogenix CEO)
- Auditor De Visser Gray LLP nominated for reappointment; audit fees were $77,000 for FY2025 vs $60,500 for FY2024
- Record date for voting: February 10, 2026; 9,787,161 common shares outstanding
- Top holders: Janus Henderson (16.3%), Cormorant Global Healthcare (10.82%), CEO Ian McDonald (10.27%)
- No financial results, guidance, or operational milestones reported in this filing
Financial Impact
No financial impact — routine proxy filing with no earnings or material transaction
Risk Factors
- Clinical-stage biotech with no approved products — binary pipeline risk
- CEO Ian McDonald holds 361,765 warrants at $1.70 expiring December 2028, representing potential dilution of ~3.7% of outstanding shares if exercised
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001062993-26-003005 |
| Exhibit: exhibit99-2.htm | 0001062993-26-003005 |
| Exhibit: exhibit99-1.htm | 0001062993-26-003005 |
| Exhibit: exhibit99-4.htm | 0001062993-26-003005 |
| Exhibit: exhibit99-5.htm | 0001062993-26-003005 |
| Document: form6k.htm | 0001062993-26-003005 |
| Document: 0001062993-26-003005-index-headers.html | 0001062993-26-003005 |
| Document: 0001062993-26-003005-index.html | 0001062993-26-003005 |
| Document: 0001062993-26-003005.txt | 0001062993-26-003005 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | 6-K | $49.79 | awaiting T+20 | — | $54.06 (+8.57%) |
Jun 3, 2026 20w ago | 6-K | $74.42 $67.60 | ▼ −9.16% | ▼ −8.16% | $54.06 (−27.36%) |
Jun 2, 2026 21w ago | 6-K | $76.78 $66.54 | ▼ −13.34% | ▼ −11.77% | $54.06 (−29.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers